ArticleCell and tissue research2010
β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder.
Article in Cell and tissue research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials.International urology and nephrology · 2014Pooled it
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Age-dependent effects of the βPflugers Archiv : European journal of physiology · 2024Article
- Inside the Biology of the β3-Adrenoceptor.Biomolecules · 2024Review
- Inhibition of prejunctional parasympathetic pathways by βFrontiers in pharmacology · 2023Article
- Transient receptor potential vanilloid type 4 (TRPV4) in urinary bladder structure and function.Current topics in membranes · 2022Review
- Mirabegron in the Management of Overactive Bladder Syndrome.International journal of women's health · 2022Review
- Additive effects of intravenous and intravesical application of vibegron, a βNaunyn-Schmiedeberg's archives of pharmacology · 2020Article
- βBritish journal of pharmacology · 2020Article
- Agonist-induced desensitisation of βBritish journal of pharmacology · 2019Review
- βBritish journal of pharmacology · 2019Review
- Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB).Current urology reports · 2019Review
- Everything You Always Wanted to Know about βCells · 2019Review
- The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.Therapeutic advances in urology · 2018Review
- The aging bladder insights from animal models.Asian journal of urology · 2018Review
- Incontinence: How do βNature reviews. Urology · 2017Article
- On the Site and Mechanism of Action of βInternational neurourology journal · 2017Review
- Clinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome.Therapeutic advances in urology · 2015Review
- Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms.International journal of clinical and experimental pathology · 2015Article
- Neural control of the lower urinary tract.Comprehensive Physiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
β(3)-Adrenergic receptor agonists are currently under clinical development for the treatment of overactive bladder, a condition that is prevalent in postmenopausal women. These agents purportedly relax bladder smooth muscle through a direct action at the myocyte β(3)-receptor. The aim of this study was to examine the expression of the individual beta-adrenergic receptors in full thickness sections from ageing human female bladder. We obtained a series of rabbit polyclonal antibodies generated against each of the three β-adrenergic receptors, and validated their receptor specificity in CHOK1 cells expressing each of the individual receptors. Immunostaining for β(1), β(2), and β(3) were each more prominent in the urothelium than in the detrusor, with all receptors expressed in the same cell types, indicating co-expression of all three receptors throughout the urothelium in addition to the detrusor. Staining of all receptors was also observed in suburothelial myofibroblast-like cells, intramural ganglion cells, and in Schwann cells of intramural nerves. The β(3)-receptor in the human urothelium appears to be functional, as two different selective β(3)-receptor agonists, TAK677 and BRL37344, stimulate cAMP formation in URO tsa cells. Densitometry analysis indicates a persistent expression of all receptors throughout the bladder with increasing age, with the exception of the β(2)-receptor in the urothelium of the trigone, which appears to decrease slightly in older women. These data indicate that β(3)-receptor expression is maintained with age, but may function in concert with other β-receptors. Activation of the myocyte receptor may be influenced by action on non-myocyte structures including the intramural ganglion cells and myofibroblasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.